Developer docs
API playgroundTry for free, no card

Search company profiles

Sirona Biochem

Full company profile

uuid00063qw

Namestring
Sirona Biochem
Legal namestring
Sirona Biochem Corp.
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Sirona Biochem Corp. is a Vancouver-based, publicly traded (CVE:SBM) biotechnology company founded in 2006 that develops and licenses proprietary compounds to global customers in the cosmetic ingredients and pharmaceutical drug discovery sectors. Its product surface is concentrated in dermatological and anti-aging applications, including skin depigmenting and anti-aging agents, anchored by a proprietary chemistry platform whose core IP traces to the 2011 acquisition of TFChem. The company is led by founder, Chairman and CEO Howard J. Verrico, with Christopher Hopton as CFO, Géraldine Deliencourt-Godefroy as CSO, and Michelle Seltenrich as VP of Operations, supported by a small team of 11-50 employees.

The business model is asset-light and contract-based: Sirona generates revenue by licensing its proprietary compounds to global cosmetic, skincare, and pharmaceutical companies for use in their product formulations and drug discovery pipelines. Pricing and contract economics are not publicly disclosed, and no named licensees are available in the source data. The customer base spans two use-case segments — a primary cosmetic ingredients segment serving companies seeking differentiated anti-aging and skincare actives, and a secondary pharmaceutical/drug discovery segment — with a horizontal segmentation approach. In April 2025 the company added a strategic layer through Promura GmbH, which invested CAD $3 million via convertible debentures and co-formed Sirona Laboratories, a jointly controlled joint venture in Luxembourg, with Promura signaling up to CAD $12 million of follow-on capital contingent on due diligence to advance dermatological and cosmetic innovation. Subsequent capital activity in 2026 has shifted to debt, including CAD $1 million loan and promissory note arrangements with 0906462 B.C. Ltd., consistent with working-capital bridging while larger strategic capital remains contingent.

Short descriptiontext

Sirona Biochem Corp. is a Vancouver-based public biotechnology company that develops and licenses proprietary compounds — primarily anti-aging and skin depigmenting actives — to global cosmetic ingredients and pharmaceutical drug discovery customers, anchored by the TFChem chemistry platform and a 2025 joint venture with Promura GmbH.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cosmetic ingredient licensing, biotechnology compound development, anti-aging skincare compounds, dermatological drug discovery, proprietary biochemical compounds
Industry2 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biotechnology & Pharmaceutical Licensing
Revenue model1 record
1Compound Licensing
TypeLicensing Royalties
Description

Sirona Biochem licenses its proprietary compounds to global companies in the cosmetic and pharmaceutical industries.

finance.yahoo.com
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sirona Biochem develops proprietary biological and chemical compounds — including anti-aging agents, skin depigmenting agents, and diabetes therapeutics — and licenses them to global companies in the cosmetic and pharmaceutical industries. The company operates as a compound licensor rather than a finished-product manufacturer, monetizing its IP portfolio through royalty and licensing agreements. Its scientific foundation stems from the 2011 acquisition of TFChem, and its dermatological focus is being scaled via the 2025 Sirona Laboratories joint venture in Luxembourg.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sirona Biochem specializes in cosmetic ingredient development and drug discovery. The company licenses proprietary compounds to global companies. Through its joint venture Sirona Laboratories (formed with Promura GmbH in Luxembourg), the company focuses on dermatological and cosmetic innovation, particularly anti-aging products. However, no specific named products or detailed product information are available in the provided sources.

Product and service3 records
1Anti-aging cosmetic compounds
CategoryCosmetic ingredients
2Skin depigmenting agents
CategoryCosmetic ingredients
3Diabetes therapeutics
CategoryPharmaceutical drug discovery
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage dermatology company developing topical branded and generic products. Comparable small-cap dermatology biotech with proprietary formulation/IP-led pipeline similar to Sirona's compound-licensing approach.

TypeDirect peer
Description

Clinical-stage biopharma developing treatments for diabetes and metabolic disease. Comparable small-cap biotech with similar licensing/partnership-driven commercial model in cardiometabolic indications.

TypeBroad incumbent
Description

Global dermatology leader with broad prescription, aesthetic, and consumer skincare portfolio. Operates in the same dermatology/anti-aging space and is a likely licensing counterparty or competitor for Sirona's compounds.

4Revance Therapeutics
TypeDirect peer
Description

Specialty aesthetics/dermatology biotech focused on injectable and topical products. Highly comparable to Sirona's dermatology/anti-aging compound development and licensing-oriented commercialization model.

5Lipidor AB
TypeEmerging player
Description

Swedish specialty pharma/cosmeceutical developer using proprietary lipid-based delivery technology. Small-cap peer with a similar licensing-oriented model in dermatology and skin care.

TypeDirect peer
Description

Dermatology-focused biopharma developing novel topical therapies. Direct peer in the dermatology specialty pharmaceutical space with comparable size and licensing/partnering strategy.

7Evolus
TypeDirect peer
Description

Aesthetic medicine biotech commercializing injectable and topical products. Comparable small-cap aesthetics biotech with licensing-driven commercial model relevant to Sirona's anti-aging focus.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with a leading aesthetics franchise (Botox, CoolSculpting, SkinMedica). Operates broadly in the same dermatology/aesthetics space and is a potential partner or acquirer for Sirona's anti-aging assets.

9Mibelle Group
TypeEmerging player
Description

Swiss developer of proprietary cosmetic and skincare active ingredients. Comparable to Sirona as a cosmeceutical ingredient developer with licensing relationships to global beauty brands.

TypeDirect peer
Description

Small-cap clinical biotech developing peptide therapeutics for diabetes and metabolic diseases. Closely comparable to Sirona's diabetes therapeutic pipeline on both indication and company scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sirona Biochem

Biotechnology & Pharmaceutical Licensingsironabiochem.com

Sirona Biochem Corp. is a Vancouver-based public biotechnology company that develops and licenses proprietary compounds — primarily anti-aging and skin depigmenting actives — to global cosmetic ingredients and pharmaceutical drug discovery customers, anchored by the TFChem chemistry platform and a 2025 joint venture with Promura GmbH.

What Sirona Biochem does

Sirona Biochem Corp. is a Vancouver-based, publicly traded (CVE:SBM) biotechnology company founded in 2006 that develops and licenses proprietary compounds to global customers in the cosmetic ingredients and pharmaceutical drug discovery sectors. Its product surface is concentrated in dermatological and anti-aging applications, including skin depigmenting and anti-aging agents, anchored by a proprietary chemistry platform whose core IP traces to the 2011 acquisition of TFChem. The company is led by founder, Chairman and CEO Howard J. Verrico, with Christopher Hopton as CFO, Géraldine Deliencourt-Godefroy as CSO, and Michelle Seltenrich as VP of Operations, supported by a small team of 11-50 employees.

The business model is asset-light and contract-based: Sirona generates revenue by licensing its proprietary compounds to global cosmetic, skincare, and pharmaceutical companies for use in their product formulations and drug discovery pipelines. Pricing and contract economics are not publicly disclosed, and no named licensees are available in the source data. The customer base spans two use-case segments — a primary cosmetic ingredients segment serving companies seeking differentiated anti-aging and skincare actives, and a secondary pharmaceutical/drug discovery segment — with a horizontal segmentation approach. In April 2025 the company added a strategic layer through Promura GmbH, which invested CAD $3 million via convertible debentures and co-formed Sirona Laboratories, a jointly controlled joint venture in Luxembourg, with Promura signaling up to CAD $12 million of follow-on capital contingent on due diligence to advance dermatological and cosmetic innovation. Subsequent capital activity in 2026 has shifted to debt, including CAD $1 million loan and promissory note arrangements with 0906462 B.C. Ltd., consistent with working-capital bridging while larger strategic capital remains contingent.

Sirona Biochem firmographics

Firmographics
Name
Sirona Biochem
Legal name
Sirona Biochem Corp.
Website
https://sironabiochem.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Sirona Biochem Corp. is a Vancouver-based public biotechnology company that develops and licenses proprietary compounds — primarily anti-aging and skin depigmenting actives — to global cosmetic ingredients and pharmaceutical drug discovery customers, anchored by the TFChem chemistry platform and a 2025 joint venture with Promura GmbH.
Ownership category
akta.pro rank

Sirona Biochem industry classification

Industry
Product category
Biotechnology & Pharmaceutical Licensing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cosmetic ingredient licensing
  • Biotechnology compound development
  • Anti-aging skincare compounds
  • Dermatological drug discovery
  • Proprietary biochemical compounds

Where Sirona Biochem is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Sirona Biochem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Compound Licensing: Sirona Biochem licenses its proprietary compounds to global companies in the cosmetic and pharmaceutical industries.

Sirona Biochem product offering

Product offering

Core offering

Sirona Biochem develops proprietary biological and chemical compounds — including anti-aging agents, skin depigmenting agents, and diabetes therapeutics — and licenses them to global companies in the cosmetic and pharmaceutical industries. The company operates as a compound licensor rather than a finished-product manufacturer, monetizing its IP portfolio through royalty and licensing agreements. Its scientific foundation stems from the 2011 acquisition of TFChem, and its dermatological focus is being scaled via the 2025 Sirona Laboratories joint venture in Luxembourg.

Product overview

Sirona Biochem specializes in cosmetic ingredient development and drug discovery. The company licenses proprietary compounds to global companies. Through its joint venture Sirona Laboratories (formed with Promura GmbH in Luxembourg), the company focuses on dermatological and cosmetic innovation, particularly anti-aging products. However, no specific named products or detailed product information are available in the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anti-aging cosmetic compounds
  • Skin depigmenting agents
  • Diabetes therapeutics

Companies that use Sirona Biochem

Customer profile

Segments2 records

Ideal customer profiles2 records

Sirona Biochem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sirona Biochem partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Sirona Biochem competitors and assessment

Company assessment

Direct peers

  • Sol-Gel Technologies: Clinical-stage dermatology company developing topical branded and generic products. Comparable small-cap dermatology biotech with proprietary formulation/IP-led pipeline similar to Sirona's compound-licensing approach.
  • Lexicon Pharmaceuticals: Clinical-stage biopharma developing treatments for diabetes and metabolic disease. Comparable small-cap biotech with similar licensing/partnership-driven commercial model in cardiometabolic indications.
  • Revance Therapeutics: Specialty aesthetics/dermatology biotech focused on injectable and topical products. Highly comparable to Sirona's dermatology/anti-aging compound development and licensing-oriented commercialization model.
  • Arcutis Biotherapeutics: Dermatology-focused biopharma developing novel topical therapies. Direct peer in the dermatology specialty pharmaceutical space with comparable size and licensing/partnering strategy.
  • Evolus: Aesthetic medicine biotech commercializing injectable and topical products. Comparable small-cap aesthetics biotech with licensing-driven commercial model relevant to Sirona's anti-aging focus.
  • Zealand Pharma: Small-cap clinical biotech developing peptide therapeutics for diabetes and metabolic diseases. Closely comparable to Sirona's diabetes therapeutic pipeline on both indication and company scale.

Broad incumbents

  • Galderma: Global dermatology leader with broad prescription, aesthetic, and consumer skincare portfolio. Operates in the same dermatology/anti-aging space and is a likely licensing counterparty or competitor for Sirona's compounds.
  • AbbVie (Allergan Aesthetics): Global pharmaceutical incumbent with a leading aesthetics franchise (Botox, CoolSculpting, SkinMedica). Operates broadly in the same dermatology/aesthetics space and is a potential partner or acquirer for Sirona's anti-aging assets.

Emerging players

  • Lipidor AB: Swedish specialty pharma/cosmeceutical developer using proprietary lipid-based delivery technology. Small-cap peer with a similar licensing-oriented model in dermatology and skin care.
  • Mibelle Group: Swiss developer of proprietary cosmetic and skincare active ingredients. Comparable to Sirona as a cosmeceutical ingredient developer with licensing relationships to global beauty brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Sirona Biochem social profiles

Digital presence

Sirona Biochem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sirona Biochem leadership team

Management profile

Number of profiles

Profiles4 records

Sirona Biochem subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sirona Biochem funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sirona Biochem M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirona Biochem

What does Sirona Biochem do?

Sirona Biochem develops proprietary biological and chemical compounds — including anti-aging agents, skin depigmenting agents, and diabetes therapeutics — and licenses them to global companies in the cosmetic and pharmaceutical industries. The company operates as a compound licensor rather than a finished-product manufacturer, monetizing its IP portfolio through royalty and licensing agreements. Its scientific foundation stems from the 2011 acquisition of TFChem, and its dermatological focus is being scaled via the 2025 Sirona Laboratories joint venture in Luxembourg.

Is Sirona Biochem a public or private company?

Sirona Biochem is a public company. It is classified as public and is currently operating.

When was Sirona Biochem founded?

Sirona Biochem was founded in 2006. It employs 1 to 10 people.

Where is Sirona Biochem based?

Sirona Biochem is headquartered in Vancouver, Canada, in the North America region.

How does Sirona Biochem make money?

One revenue line is on record: compound Licensing.

Who are Sirona Biochem's main competitors?

Direct peers on record are Sol-Gel Technologies, Lexicon Pharmaceuticals, Revance Therapeutics, Arcutis Biotherapeutics, Evolus and Zealand Pharma. Broad incumbents are Galderma and AbbVie (Allergan Aesthetics). Emerging players are Lipidor AB and Mibelle Group.

Does Sirona Biochem have an API?

No public API is recorded for Sirona Biochem.

What industry is Sirona Biochem in?

Sirona Biochem's product category is Biotechnology & Pharmaceutical Licensing. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cosmetics BusinessSirona and Obagi ink skin lightening compound dealSirona Biochem executed a global exclusive licensing agreement with Obagi Medical Products for the skin lightening compound TFC-849. Sirona will receive licensing fees and ongoing royalties, while Obagi handles manufacturing, distribution, and global sales. The deal covers the Valeant Pharmaceuticals family, with the skin lightening market projected to reach $19.8bn by 2018.Cosmetics BusinessSirona Biochem and Obagi Medical Products to commercialise skin lightening compoundSirona Biochem and Obagi Medical Products signed a letter of intent to commercialize the skin lightening compound TFC-849, with Sirona granting Obagi a global exclusive license. Sirona will receive upfront, milestone, and royalty payments, while Obagi will develop a pipeline of compounds for global sale.Cosmetics BusinessSirona Biochem launches anti-ageing preclinical studies with Biogalenys laboratoryTFChem, a French subsidiary of Sirona Biochem, launched anti-ageing preclinical studies with CRO Biogalenys, funded by Bpifrance and Haute Normandie. The studies aim to validate compounds and determine optimal commercial applications and joint venture partners. Analysts forecast the anti-ageing market to reach nearly US$285bn by 2018.openPR.comUnited States Antifreeze Proteins Market Set to Soar: Innovations Driving Unprecedented Growth 2025 | Major key players - Unilever, Kaneka Corp, Sirona Biochem.The antifreeze proteins market is projected to grow significantly from 2024 to 2031, with key players including Unilever, Kaneka Corp, and Sirona Biochem. Europe's market is expected to grow at over 21% CAGR, led by Type I AFP with a 42% share in 2024. Growth is driven by food, pharmaceutical, and biotech applications.AInvestAssessing Sirona Biochem's Strategic Resilience Amid Financial CrisisSirona Biochem, a Canadian-French biotech, faces financial turmoil including a cease trade order and a $3 million investment collapse, but advances its patented anti-aging compound GlycoProteMim™. The company pivots to direct commercialization via a 2025 serum launch, targeting a $12.5B market, while licensing deals provide revenue buffers.BarchartSirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbHSirona Biochem announced a strategic investment agreement and the formation of a new joint venture with Promura GmbH, a German investor, on April 22, 2025. The deal involves a private placement of $3 million CAD and Promura's potential investment of up to $12 million CAD into Sirona Laboratories, a subsidiary focused on dermatological and cosmetic innovation.Cosmetics BusinessSirona Biochem announces patent for anti-ageing family of compoundsSirona Biochem's subsidiary TFChem filed a patent application for a second generation of glycoprotein compounds. The technology, derived from Antarctic fish proteins, targets anti-ageing cosmetics and may later extend to consumer packaged goods and prescription pharmaceuticals.GlobeNewswireSIRONA BIOCHEM Corporate Update April 2024Sirona Biochem reported at its AGM that shareholders supported its strategy, and it closed financing below its anticipated goal. The company plans to launch its first GlycoProteMimTM-containing cosmetic products in Europe and North America in early 2025, with expansion to other markets. It also advanced a global licensing agreement with Allergan Aesthetics for TFC-1067.YahooSirona Biochem Announces Close of Private PlacementSirona Biochem Corp. closed a private placement on April 4, 2024, raising $132,500 CAD through the sale of 1,325,000 units at $0.10 per unit. The company intends to use the proceeds for general working capital purposes. No insiders participated in the transaction, and statutory hold periods apply until August 4, 2024.GlobeNewswireSirona Biochem Announces Close of Private PlacementSirona Biochem Corp. closed a private placement raising $132,500 CAD through the issuance of 1,325,000 units at $0.10 per unit. The company stated that the proceeds will be utilized for general working capital purposes. No insiders participated in the transaction, and statutory hold periods apply to the issued securities.